I-MAB, a Shanghai-based startup has agreed with MorphoSys on the exclusive development and commercialization of MOR202 in China, Taiwan, Hong Kong and Macau. The investigational drug MOR202 is a human HuCAL antibody directed against the CD38 target. Scientifically proven, CD38 is a highly expressed target protein in multiple myeloma. In addition to the treatment of multiple myeloma, studies have found that CD38 antibodies have a therapeutic effect on a variety of solid tumors and autoimmune diseases. MorphoSys is completing Phase 1 / 2a clinical studies of MOR202 in Germany and Austria.

China Bio news release, December 2, 2017